Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed With Type 1 Diabetes Aged ≥1 to <36 Years
NCT07222332 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed With Type 1 Diabetes Aged ≥1 to <36 Years
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- February 5, 2026
- Completion date
- July 31, 2028
- Enrollment
- 300 (estimated)
- Sites
- 131
Conditions
As the registry lists them; a condition with its own page is linked.